![]() |
|
|
Vol. 63, Issue 4, 925-932, April 2003
Department of Pharmacy, Center of Drug Research, University of Munich, Munich, Germany (U.G.B.H., A.M.V., V.M.D.); and Department of Medicine, Division of Cardiology, Emory University, Atlanta, Georgia (D.S., K.K.G.)
| |
Abstract |
|---|
|
|
|---|
Resveratrol (RV), a polyphenolic stilbene derivative, has been proposed to exert a plethora of beneficial cardiovascular effects. Of these, in particular, inhibition of vascular smooth muscle cell (VSMC) proliferation shows great promise for preventing cardiovascular disease. In the present study, we show that RV leads to a reversible arrest in early S phase of the VSMC cycle, accompanied by an accumulation of hyperphosphorylated retinoblastoma protein. In contrast to studies with other cell systems, RV decreases cellular levels of the cyclin-dependent kinase inhibitors p21Cip1 and p27Kip1. This is of particular interest because phosphorylated p53 protein (serine15) is strongly enhanced by this substance. We further found that RV only slightly inhibits phosphorylation of Erk 1/2, protein kinase B/Akt, and p70S6 kinase upon serum stimulation. Thus, inhibition of these kinases is not likely to contribute to the cell cycle effect of RV. Importantly, the observed S phase arrest is not linked to an increase in apoptotic cell death: there was no detectable increase in apoptotic nuclei and in levels of the proapoptotic protein Bax. This is the first study elucidating the molecular pathways mediating the antiproliferative properties of RV in VSMCs.
| |
Introduction |
|---|
|
|
|---|
Vascular
smooth muscle cells (VSMCs) in the arterial media are fully
differentiated to play their physiological roles as regulators of
vascular wall tension. They proliferate at low indices or persist in
the G0 phase of the cell cycle. Entry into and
progression through the cell cycle by vascular cells is considered a
key event in vascular proliferative diseases such as primary
atherosclerosis and postangioplasty restenosis (Jackson and Schwartz,
1992
; Braun-Dullaeus et al., 1998
). Thus, the VSMC cycle provides a
potent therapeutic target, as demonstrated by studies successfully
preventing restenosis after angioplasty by using antisense
oligodeoxynucleotides against cell cycle-regulatory genes or gene
transfer of nonphosphorylated retinoblastoma protein (Rb) (Morishita et
al., 1993
; Chang et al., 1995
).
trans-Resveratrol (RV,
trans-3,5,4'-trihydroxystilbene) is a polyphenolic stilbene
derivative found in a narrow range of spermatophytes, of which vines,
peanuts, and pines are the prime representatives. As a major
constituent of red wine RV has been proposed to account, at least in
part, for the beneficial effects attributed to this beverage in
cardiovascular diseases (Soleas et al., 2001
; Wu et al., 2001
). In vivo
studies, for example, suggested that RV can protect against intimal
hyperplasia after endothelial denudation in an experimental rabbit
model (Zou et al., 2000
). More recent data imply that RV decreases
NAD(P)H oxidase activity in rat aortic homogenates (Orallo et al.,
2002
). Our own studies showed that RV suppresses angiotensin II-induced
VSMC hypertrophy (Haider et al., 2002
). An antiproliferative
property presumably contributes to cardio- and vasoprotective effects
of this natural compound (Zou et al., 1999
; Mizutani et al., 2000
).
Although this property of RV is documented for various cell types,
including VSMCs, it seems that, depending on the cell type
investigated, there are considerable mechanistic differences in the way
the cell cycle is altered (Hsieh et al., 1999
; Zou et al., 1999
; Adhami
et al., 2001
; Sgambato et al., 2001
). For VSMCs in particular, the
underlying mechanism has never been thoroughly investigated. However,
deeper knowledge of the molecular basis of RV effects is crucial to
validate the potential of this substance as a beneficial agent in
cardiovascular disease. Therefore, this study was aimed to gain further
insight into the pathways mediating inhibition of VSMC proliferation by RV.
| |
Materials and Methods |
|---|
|
|
|---|
Reagents. Materials were obtained from the following suppliers: antibodies against phospho-Akt (Ser473), phospho-p70S6k (Thr421/Ser424), phospho-Erk 1/2 MAPK (Thr202/Tyr204), phospho-p38 MAPK (Thr180/Tyr182), phospho-p53 (Ser15) as well as Akt, Erk1/2, p70S6k, and p53 (mouse monoclonal 1C12) were from Cell Signaling Technology (Frankfurt, Germany). Antibodies against Bax, p27, p21, and retinoblastoma protein (Rb) as well as the BrdU flow cytometry kit were purchased from BD Biosciences (Heidelberg, Germany). Hoechst 33342, RV, and propidium iodide (PI) were from Sigma (Taufkirchen, Germany). Cell death detection ELISAPLUS was from Roche (Mannheim, Germany). Horseradish peroxidase-conjugated goat anti-rabbit secondary antibody was purchased from Dianova (Hamburg, Germany). Serotec (Eching, Germany) provided horseradish peroxidase-conjugated goat anti-mouse antibody. Aphidicolin (Aph) was from Calbiochem (Schwalbach, Germany). Calf serum was from Invitrogen (Karlsruhe, Germany). Phenol red-free Dulbecco's modified Eagle's medium was obtained from Pan Biotech GmbH (Aidenbach, Germany).
Cell Culture.
VSMCs were isolated from male Sprague-Dawley
rat thoracic aortas by enzymatic digestion as described previously
(Griendling et al., 1991
). Cells were grown in phenol red-free
Dulbecco's modified Eagle's medium supplemented with 10% calf serum,
2 mM glutamine, 100 units/ml penicillin, and 100 µg/ml streptomycin (growth medium) and passaged twice a week by harvesting with
trypsin/EDTA and seeding into 75-cm2 flasks. For
experiments, cells between passage 7 and 15 were used at 70 to 95% confluence.
Western Blotting.
VSMCs in 60-mm dishes at 70 to 95%
confluence were made quiescent in serum-free medium overnight if not
otherwise indicated. Cells were preincubated with RV, Aph, or vehicle
(dimethyl sulfoxide) for 30 min before stimulation with 10% calf serum
for the indicated times. After treatment, cells were harvested on ice,
and Western blot was performed as described previously (Ushio-Fukai et
al., 1999
). Briefly, equal amounts of proteins (60 µg for Rb, 20 µg for all other targets) were separated by SDS-polyacrylamide gel electrophoresis (7.5% for Rb, 10% for MAPK,
p70S6 kinase, protein kinase B (PKB)/Akt, and
p53, 15% for Bax, p21Cip1, and
p27Kip1) and transferred to a nitrocellulose
membrane (Hybond ECL; Amersham Biosciences, Freiburg, Germany). Equal
protein loading was controlled by Coomassie Blue staining of gels.
Membranes were blocked in 5% dry milk powder in Tris-buffered saline
containing 1% Tween 20 (1 h) and incubated overnight at 4°C with the
specified antibody. Proteins were visualized by secondary antibodies
conjugated to horseradish peroxidase and the Renaissance Plus reagent
(PerkinElmer Life Science, Köln, Germany) and quantified
with a Kodak Digital Science image station 440 cf (PerkinElmer Life
Science, Köln, Germany). For
-irradiation (IR) experiments,
cells were treated with 10 Gy for 12 h before harvesting.
Cell Cycle Analysis. Cells were seeded at a density of 50,000 cells/well in six-well plates and kept in growth medium for 24 h. After serum starvation for 4 days, cells were pretreated with or without RV for 30 min using the indicated concentrations and subsequently stimulated with 10% calf serum. Twenty-two hours later cells were trypsinized, washed once with phosphate-buffered saline (PBS), and resuspended in a hypotonic PI solution containing 0.1% (v/v) Triton X-100, 0.1% (w/v) sodium citrate, and 50 µg/ml PI. After incubation at 4°C overnight, PI-stained nuclei were analyzed by flow cytometry (FACScalibur; BD Biosciences, Germany).
Identification of Actively Cycling Cells with BrdU/7-Amino-actinomycin Costaining. Cells were seeded at a density of 80,000 cells/well in six-well plates and made quiescent by serum withdrawal for 4 days. Cells were stimulated by addition of 10% calf serum. After 4 h, 1 µM Aph was added and cells were grown for another 15 h in the presence of Aph and 10% calf serum. Subsequently, Aph was removed by washing cells once with PBS before adding fresh growth medium containing 2 µM Aph, 100 µM RV, or vehicle (dimethyl sulfoxide) for another 4 h. The cells were then pulse-labeled for 30 min with 10 µM BrdU, harvested, and processed as described by the manufacturer. This two-color flow cytometric analysis permits the enumeration and characterization of cells that are actively synthesizing DNA (BrdU incorporation) in terms of their cell cycle position (defined by 7-Amino-actinomycinstaining intensities). Analysis of stained cells was performed by flow cytometry (FACScalibur).
To determine whether RV-induced cell cycle block is reversible, cells were seeded at a density of 80,000 cells/well in six-well plates. After serum starvation for 2 days, cell cycle arrest was induced by treatment with 100 µM RV in growth medium for 19 h. RV was removed by washing cells once with PBS. Afterward, fresh growth medium with or without 100 µM RV was added and cells were grown for another 4 h. During the last 30 min, cells were pulse labeled with 10 µM BrdU and processed as described above.Cytotoxicity. Cells were grown to 80% confluence, serum-starved overnight, and subsequently stimulated with 10% calf serum with or without RV for 22 h, trypsinized, washed once with PBS, stained with 2.5 µg/ml PI for 5 min, and analyzed by flow cytometry (FACScalibur). Cells unable to exclude PI (PI-stained nuclei) were considered dead.
Apoptosis. Apoptotic cell death was excluded by 1) nucleosome ELISA using the cell detection ELISAPLUS kit from Roche (Mannheim, Germany) according to the manufacturers instruction; 2) staining of apoptotic nuclei with Hoechst 33342 by subsequent fluorescence microscopy (Axiovert 25; Carl Zeiss, Jena, Germany), and 3) cell cycle analysis (lack of a sub-G1-peak). In all cases, cells were seeded, grown for 24 h, serum-starved overnight, and subsequently treated with up to 100 µM RV or vehicle for 24 h.
Statistical Analysis. All experiments were performed at least three times. Results are expressed as mean ± S.E. Statistical analysis was performed by analysis of variance followed by a Dunnett multiple comparison test or by a paired two-tailed student's t test using Prism version 3.00 for Windows (GraphPad Software). P values <0.05 were considered significant.
| |
Results |
|---|
|
|
|---|
Resveratrol Reversibly Inhibits Cell Cycle Progression in
VSMCs.
Previous studies demonstrate an antiproliferative effect of
RV in various cancer cell lines (Adhami et al., 2001
; Sgambato et al.,
2001
) as well as in cardiovascular cells (Hsieh et al., 1999
; Zou et
al., 1999
); Consistent with these results, we observed a significant
dose-dependent reduction of serum-induced VSMC proliferation in cells
treated with 10 to 100 µM RV (data not shown). To elucidate the exact
mechanism underlying the antimitogenic effect of RV in VSMCs, we
performed cell cycle analysis of cells treated with various
concentrations of RV for 22 h (Fig.
1A). These data suggest a dose-dependent
accumulation of RV-treated cells at the
G1/S-interphase, with 100 µM RV leading to a
complete block in cell cycle progression. The observed DNA replication
block is, however, reversible, because cells arrested by RV treatment
are still able to cycle through S phase when RV is removed (Fig. 1B).
Neither Hoechst, PI staining, a nucleosome ELISA, nor cell cycle
analysis revealed cytotoxic effects at this concentration (data not
shown and Fig. 1A, f); therefore, 100 µM RV was used for all other
cell cycle experiments.
|
Resveratrol Only Weakly Affects Phosphorylation of PKB/Akt, Erk
1/2, and p70S6 Kinase.
It is widely accepted that
mitogens promote cell cycle progression of quiescent cells via the
PKB/Akt and the Erk 1/2 signaling cascades, both critically involved in
accumulation of D-type cyclins in the G1 phase
(Sherr and Roberts, 1999
). p70S6 kinase is
activated downstream of PKB/Akt and Erk 1/2 in VSMCs (Eguchi et al.,
1999
) and has been implicated in cell proliferation (Vinals et al.,
1999
). We therefore hypothesized that inhibition of these kinases might
contribute to the observed antimitogenic effect of RV. As shown in Fig.
2A, serum stimulation of VSMCs led to a
rapid increase in PKB/Akt, Erk 1/2, and p70S6
kinase phosphorylation that was sustained for several hours. We were
unable to detect an induction of p38 MAPK phosphorylation by serum in
VSMCs. To our surprise, RV only weakly inhibited PKB/Akt and
p70S6 kinase phosphorylation and failed to
significantly reduce Erk 1/2 phosphorylation, as assayed 30 min after
serum stimulation (Fig. 2B). Because RV affected cell cycle progression
in concentrations as low as 10 µM and arrest was complete at 100 µM
RV, inhibition of these kinases is unlikely to primarily account for
this effect.
|
Resveratrol Increases Retinoblastoma Protein Phosphorylation.
In late G1 phase, cells reach the so-called
restriction point. Beyond this point, cells are committed to DNA
replication, and further cell cycle progression proceeds independently
of growth factor stimulation (Sherr, 1996
). Rb is a key component of
the molecular network controlling the restriction point.
Hypophosphorylated Rb binds the E2F family of transcription factors,
and thus inhibits transcription of E2F-responsive genes necessary for
cell cycle progression. Hyperphosphorylation of Rb by cyclin-dependent
kinases leads to dissociation of Rb from promotor-bound E2F, allowing transcription of E2F-regulated genes (Sherr, 1996
; DePinho, 1998
). Antimitogenic agents affecting the G1 phase, such
as inhibitors of the phosphoinositol 3-kinase and the
p70S6 kinase pathway, such as wortmannin or
rapamycin, keep Rb in the hypophosphorylated, active state (data not
shown; Vinals et al., 1999
). Therefore, we investigated the impact of
RV on Rb hyperphosphorylation. As shown in Fig.
3A, serum alone led to a continuous
increase of Rb hyperphosphorylation over 22 h, first detectable
after 6 to 8 h. Interestingly, pretreatment of cells with RV (100 µM) did not prevent Rb hyperphosphorylation; rather, it resulted in a
dramatic increase (1.7-fold at 22 h) in hyperphosphorylated Rb
(Fig. 3B).
|
Resveratrol Does Not Enhance p21Cip1 and
p27Kip1 Protein Expression.
Because
several studies have linked RV with an up-regulation of
p21Cip1 (Ahmad et al., 2001
; Hsieh et al.,
1999
), we speculated that RV may induce cell cycle arrest through
up-regulation of the cell cycle inhibitors
p21Cip1 and p27Kip1. Even
though Cip/Kip proteins are potent inhibitors of cyclin E- and
A-dependent kinases, which are rate-limiting and essential for DNA
replication, they act as positive regulators of cyclin D-dependent
kinases that phosphorylate Rb (Sherr and Roberts, 1999
). Figure
4A shows time courses of
p21Cip1 and p27Kip1
protein levels in calf serum-stimulated VSMCs. As expected,
p21Cip1 levels were low in quiescent cells but
up-regulated in late G1 phase in response to
serum. In contrast, p27Kip1 levels decreased
over time upon stimulation with serum as reported before (Sherr and
Roberts, 1999
). In striking contrast to results from other groups using
different cell systems, in VSMCs, RV induced neither
p21Cip1 nor p27Kip1
protein expression. Quite to the contrary, RV substantially reduced protein levels of these CDK inhibitors (Fig. 4B). Together, these results suggest that RV does not affect cell cycle progression in
G1 phase.
|
Resveratrol Leads to Cell Cycle Arrest in Early S Phase.
Cell
cycle analysis revealed that these cells require about 10 to 12 h
to reach S phase and 22 to 24 h to complete one cell cycle (data
not shown). Therefore, we assessed hyperphosphorylated Rb levels after
12 and 22 h of serum stimulation in the presence of Aph (1 µM),
a well characterized inhibitor of DNA polymerase
and
, or RV
(100 µM). Neither Aph nor RV altered the Rb phosphorylation state
until 12 h, consistent with the idea that both compounds do not
affect G1 phase. However, after 22 h, both
substances clearly increased hyperphosphorylated forms of Rb.
Similarly, the expression of p21Cip1 and
p27Kip1 was not changed until 12 h of
treatment with Aph and RV, respectively, and after 22 h,
p27Kip1 levels seemed lower in response to both
stimuli. Interestingly, unlike RV, Aph did not lead to a decrease of
p21Cip1 protein levels after 22 h (Fig.
5A). Thus, RV seems to act similarly, although not identically, to the DNA polymerase inhibitor Aph.
|
Resveratrol Enhances Serine15 Phosphorylation of
p53.
Gottifredi et al. (2001)
have recently shown that blocked DNA
replication induces increased levels of
serine15-phosphorylated p53; however, p53 is
functionally impaired because serine15-phosphorylated p53 is not accompanied by p21
accumulation. We therefore examined whether RV leads to increased
levels of serine15-phosphorylated p53. Indeed,
Western blots depicted in Fig. 6A show a
dramatic increase in phospho-p53 levels after RV as well as Aph
treatment. Consistent with the idea that RV blocks DNA synthesis only
transiently, the increase in phosphorylated p53 was not accompanied by
an increase in p21Cip1 (Fig. 5A) and Bax levels
(Fig. 6A), both genes known to be regulated by p53 (el Deiry et al.,
1993
; Miyashita and Reed, 1995
).
|
-Irradiation Can Rescue p53 from Aph- and RV-Induced
Transcriptional Block.
Little is known about regulation of p53 in
VSMCs. Therefore, to further elucidate why enhanced p53
serine15 phosphorylation by RV and Aph is not
accompanied by increased expression of target genes such as p21 in
these cells, we performed additional experiments using IR (Fig. 6B). As
expected, IR alone and in combination with RV or Aph lead to a strong
increase in serine15-phosphorylated p53 levels.
However, in contrast to findings by Gottifredi et al. (2001)
in RKO
cells, neither RV nor Aph could prevent the augmentation of p21 levels
after IR. Interestingly, although RV, Aph, and IR increase p53
serine15 phosphorylation in VSMCs and IR also
increases p53 transactivation, total levels of p53 are unaltered.
| |
Discussion |
|---|
|
|
|---|
The present study provides valuable insight into the molecular
mechanism used by RV to mediate its antiproliferative effect in VSMCs.
We found that, in contrast to earlier findings (Zou et al., 1999
),
RV-treated cells do not accumulate in G1 phase. Rather, they undergo a reversible DNA replication block in early S
phase, as supported by the following observations: 1) RV does not
primarily act via the MAPK or PKB/Akt signaling cascades that link
mitogenic stimuli via the G1 phase to the cell
cycle machinery (Sherr and Roberts, 1999
); 2) RV does not prevent Rb
hyperphosphorylation, as shown for antimitogenic substances affecting
G1 phase (Vinals et al., 1999
); 3) RV does not
increase p21Cip1 and
p27Kip1 protein levels, which may inhibit cyclin
E- and A-dependent kinases; 4) instead, RV clearly prevents further
cell cycle progression of VSMCs that are released from an arrest in
early S phase induced by Aph treatment; 5) RV induces a reversible S
phase arrest because cell cycle progression is restored after RV
displacement. Most interestingly, we demonstrated that RV increases
serine15-phosphorylated but transcriptionally
impaired p53, in a manner similar to that recently shown to occur in
response to substances that induce a reversible DNA replication block
(Gottifredi et al., 2001
).
When quiescent cells are exposed to mitogens, cyclin D is the first
cyclin to be induced when cells progress through
G1 phase. The Erk 1/2 signaling cascade as well
as PKB/Akt governed pathways contribute to accumulation of cyclin D and
its assembly with cyclin-dependent kinases (CDKs) 4 and 6 (Sherr and
Roberts, 1999
). Thus, both pathways play a critical role in linking
mitogenic cues to the G1 phase of the cell cycle.
p70S6 kinase, downstream of PKB/Akt and Erk 1/2
(Eguchi et al., 1999
), is thought to play a role in cell cycle
progression because of its capacity to phosphorylate the ribosomal
protein S6 in response to mitogens. Although cell cycle analysis (Fig.
1) and previously published data (Zou et al., 1999
) suggest that RV
might target G1 phase, we detected only slight
inhibition of PKB/Akt and p70S6 kinase
phosphorylation. Erk 1/2 phosphorylation is not significantly altered
at all, suggesting that factors other than these kinases mediate the
antiproliferative effect of RV. These results contrast with recent
findings from our group revealing that RV strongly inhibits
phosphorylation of PKB/Akt, Erk 1/2, and p70S6
kinase upon angiotensin II stimulation in VSMCs (Haider et al., 2002
).
Furthermore, El-Mowafy and White (1999)
have also shown an inhibition
of Erk 1/2 phosphorylation in endothelin-1-stimulated porcine coronary
arteries pretreated with RV. Thus, the effect of RV on MAPK, PKB/Akt,
and p70S6 kinase activation seems to be highly
stimulus-dependent, suggesting that RV affects neither of these kinases directly.
Basically, all signals relevant for G1
progression into S phase finally culminate in Rb hyperphosphorylation.
Rb senses and integrates a multitude of proliferative and
antiproliferative signals by interacting with members of the E2F family
of transcription factors (Weinberg, 1995
). In its hypophosphorylated,
active state, Rb forms a complex with E2F, thereby blocking its
transcriptional activation, and actively represses transcription of
cell cycle genes (DePinho, 1998
). Hyperphosphorylation of Rb, which is
accomplished first by cyclin D-dependent kinases in
mid-G1 phase and then completed by cyclin E-CDK2
leads to its dissociation from promotor-bound E2F, thus allowing
transcription of E2F-regulated genes (Sherr, 1996
; DePinho, 1998
).
Antimitogenic substances acting in G1 phase consequently prevent Rb hyperphosphorylation (Vinals et al., 1999
). In
contrast to recent findings showing that RV decreases the
hyperphosporylated form of Rb in human epidermoid carcinoma (A431)
cells (Adhami et al., 2001
), we found that in serum-activated VSMCs, RV
strongly increases Rb hyperphosphorylation.
This result led us to the hypothesis that RV might up-regulate proteins
of the Cip/Kip family of CDK inhibitors, such as
p21Cip1 and p27Kip1.
Cip/Kip family members alter the activities of cyclin D-, E-, and
A-dependent kinases. Initially, the effect of
p21Cip1 and p27Kip1 was
thought to be exclusively inhibitory, but more recent work has revealed
that Cip/Kip proteins, although potent inhibitors of cyclin E- and
A-dependent CDK2, act as positive regulators of cyclin D-dependent
kinase (Sherr and Roberts, 1999
). Consequently, we speculated that an
up-regulation of p21Cip1 or
p27Kip1 may lead to an increase in Rb
hyperphosphorylation through activation of CDK4/6, concurrently
preventing cell cycle progression by inhibiting CDK2, a kinase
indispensable for cell cycle progression. In contrast to the majority
of results obtained in different cell culture models (Hsieh et al.,
1999
; Ahmad et al., 2001
; Shih et al., 2002
), we observed a decrease of
p21Cip1 and p27Kip1
levels after 22 h of treatment. Therefore, an induction of Cip/Kip proteins can be excluded as a mechanistic reason for RV's
antimitogenic action in VSMCs.
So far all results pointed more to the possibility of a RV-mediated putative DNA replication block in early S phase instead of an interference in G1. To investigate whether RV arrests VSMCs in early S phase, we determined levels of Rb hyperphosphorylation caused by RV and, as a positive control, by the DNA polymerase inhibitor Aph, after 12 and 22 h of serum stimulation. As expected, neither RV nor Aph increases levels of Rb hyperphosphorylation until 12 h. At this time point, cells are still at the G1/S-interphase and are thus not affected by a putative S phase block. After 22 h, however, accumulation of RV- or Aph-treated cells in S phase leads to a concomitant accumulation of hyperphosphorylated Rb compared with normally progressing control cells. Consistently, p21Cip1 and p27Kip1 levels also seem to be altered only after prolonged treatment, corroborating that G1 is not affected by RV and also not, as already known, by Aph. Interestingly, in contrast to RV, Aph treatment does not down-regulate p21Cip1 protein levels, arguing against an identical mechanism of these two substances. Thus, RV seems to block DNA replication in VSMCs in a manner similar to that of the DNA polymerase inhibitor Aph but without using its exact molecular mechanism of action.
Interestingly, cell-free in vitro studies have provided evidence that
RV is an inhibitor of DNA polymerase
and
(Stivala et al., 2001
)
and of the ribonucleotide reductase (Fontecave et al., 1998
).
Experiments performed in a fibroblast cell line revealed that the
ribonucleotide reductase inhibitor hydroxyurea also leads to
accumulation of cells in early S phase, accompanied by an increase in
hyperphosphorylated Rb (Linke et al., 1996
). Two distinct studies point
to similarities between RV and hydroxyurea in terms of ribonucleotide reductase inhibition (Fontecave et al., 1998
; Rodrigue et al., 2001
).
We showed, however, that RV completely prevents further S phase
progression in cells released from Aph block. This suggests that a
preceding depletion of the deoxyribonucleotide pools is not a
prerequisite for RV-induced cell cycle arrest in VSMCs.
The tumor-suppressor protein p53 is critically involved in cell cycle
control and seems to play a key role in VSMC proliferation after
vascular injury. In this context, loss of p53 activity has been
implicated in the pathogenesis of human restenosis (Speir et al.,
1994
), and transfer of wild-type p53 gene has been shown to inhibit
VSMC proliferation in vivo and in vitro (Yonemitsu et al., 1998
). In
normally proliferating cells, p53 is maintained at low levels. This is
a consequence of the interaction with the Mdm2 protein, which targets
p53 for ubiquitination and degradation. Stress signals such as
-irradiation trigger p53 phosphorylation at a number of N-terminal
sites, which affects its affinity for Mdm2, leading to p53
stabilization (Oren, 1999
). Phosphorylation at
serine15, in particular, has been implicated in
this process (Shieh et al., 1997
; Oren, 1999
). However, more recent
data suggest that serine15 phosphorylation does
not alter p53 interaction with Mdm2. Instead, it is proposed to be
responsible for p53 transactivation by promoting interaction with cAMP
response element-binding protein binding protein/p300 (Lambert
et al., 1998
; Dumaz and Meek, 1999
; Schon et al., 2002
). This seems to
be the case in VSMCs, because IR, RV, and Aph all cause enhanced
serine15 phosphorylation but fail to increase
total levels of p53.
Our results show that a reversible block of DNA replication triggered
by substances such as Aph or RV leads to an increase of
serine15 phosphorylation of p53. However, in
striking contrast to elevated levels of
serine15-phosphorylated p53 caused by IR, DNA
replication block does not lead to enhanced levels of p21, a
p53-regulated protein. This is consistent with results recently
reported by Gottifredi et al. (2001)
. Therefore,
serine15-phosphorylated but transcriptionally
impaired p53 may be considered a marker for reversible S phase arrest.
However, there seem to be considerable mechanistic differences between
p53 regulation by Aph in different cell lines: in RKO cells used by
Gottifredi et al. (2001)
, hydroxyurea and Aph were able to suppress
induction of p21 by IR, suggesting that p53 is held in a state of
active repression. This does not seem to be the case in VSMCs because
IR increases p21 levels despite the presence of Aph or RV, respectively
(Fig. 6B). Therefore, it may be speculated that the molecular mechanism
of action of RV and Aph is different in VSMCs compared with RKO cells:
for VSMCs, active repression of p53 by Aph and RV seems less likely;
instead, it seems probable that the impaired response to p53 after RV
and Aph treatment may be because of the lack of critical modifications or cofactors of the p53 protein. That way, p53 can be considered as
partially latent, with the full transcriptional activity being restored
after IR, a stimulus known to fully activate the protein.
The induction pattern for p53 by RV and Aph was similar in our cells. We therefore conclude that our results corroborate the hypothesis that RV induces a reversible DNA replication block comparable, but not identical, with that of Aph in VSMCs.
| |
Footnotes |
|---|
Address correspondence to: Verena M. Dirsch, Ph.D., Department of Pharmacy, Center of Drug Research, Butenandtstr. 5-13, D-81377 Munich, Germany. E-mail: verena.dirsch{at}cup.uni-muenchen.de
| |
Abbreviations |
|---|
VSMC, vascular smooth muscle cell;
RV, trans-resveratrol;
MAPK, mitogen-activated protein
kinase;
Rb, retinoblastoma protein;
BrdU, bromodeoxyuridine;
PI, propidium iodide;
Aph, aphidicolin;
PKB, protein kinase B;
IR,
-irradiation;
PBS, phosphate-buffered saline;
ELISA, enzyme-linked
immunosorbent assay;
Erk, extracellular signal-regulated kinase;
CDK, cyclin-dependent kinase;
FACS, fluorescence-activated cell sorting.
| |
References |
|---|
|
|
|---|
This article has been cited by other articles:
![]() |
S. A. Gatz, M. Keimling, C. Baumann, T. Dork, K.-M. Debatin, S. Fulda, and L. Wiesmuller Resveratrol modulates DNA double-strand break repair pathways in an ATM/ATR-p53- and -Nbs1-dependent manner Carcinogenesis, March 1, 2008; 29(3): 519 - 527. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Rayalam, M. A. Della-Fera, J.-Y. Yang, H. J. Park, S. Ambati, and C. A. Baile Resveratrol Potentiates Genistein's Antiadipogenic and Proapoptotic Effects in 3T3-L1 Adipocytes J. Nutr., December 1, 2007; 137(12): 2668 - 2673. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. H. Heiss, Y. D. C. Schilder, and V. M. Dirsch Chronic Treatment with Resveratrol Induces Redox Stress- and Ataxia Telangiectasia-mutated (ATM)-dependent Senescence in p53-positive Cancer Cells J. Biol. Chem., September 14, 2007; 282(37): 26759 - 26766. [Abstract] [Full Text] [PDF] |
||||
![]() |
Z. Ungvari, Z. Orosz, A. Rivera, N. Labinskyy, Z. Xiangmin, S. Olson, A. Podlutsky, and A. Csiszar Resveratrol increases vascular oxidative stress resistance Am J Physiol Heart Circ Physiol, May 1, 2007; 292(5): H2417 - H2424. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Sareen, P. R. van Ginkel, J. C. Takach, A. Mohiuddin, S. R. Darjatmoko, D. M. Albert, and A. S. Polans Mitochondria as the primary target of resveratrol-induced apoptosis in human retinoblastoma cells. Invest. Ophthalmol. Vis. Sci., September 1, 2006; 47(9): 3708 - 3716. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. Lee and S.-K. Moon Resveratrol Inhibits TNF-{alpha}-Induced Proliferation and Matrix Metalloproteinase Expression in Human Vascular Smooth Muscle Cells J. Nutr., December 1, 2005; 135(12): 2767 - 2773. [Abstract] [Full Text] [PDF] |
||||
![]() |
U. G. B. Haider, T. U. Roos, M. I. Kontaridis, B. G. Neel, D. Sorescu, K. K. Griendling, A. M. Vollmar, and V. M. Dirsch Resveratrol Inhibits Angiotensin II- and Epidermal Growth Factor-Mediated Akt Activation: Role of Gab1 and Shp2 Mol. Pharmacol., July 1, 2005; 68(1): 41 - 48. [Abstract] [Full Text] [PDF] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||